Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-Free Intraoperative Regimen with Basiliximab in Pediatric Liver Transplant
NCT00149890Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of basiliximab in Liver transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death at 3 months. Started Mar 2004; status: completed.
02
Drugs
basiliximab
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00149890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149890.